Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 5/20 | 0.39 |
| ▸ | RXRB | P28702 | 5/20 | 0.39 |
| ▸ | RXRG | P48443 | 3/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | MPL | P40238 | 2/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451357 | 0.82 | CTSS (0.46) | KDM4ES1PR1S1PR3CTSSGABRA1 | |
| SCHEMBL26233974 | 0.80 | CCR1 (0.54) | KDM4EGAAMAPTS1PR1S1PR3 | |
| SCHEMBL4464087 | 0.76 | PTGS2 (0.43) | MAPTMEN1KMT2A | |
| SCHEMBL30895934 | 0.76 | CCR1 (0.41) | MAPTMETAP2MEN1RAB9AKMT2A | |
| SCHEMBL25389606 | 0.75 | RXRB (0.40) | KDM4EGAAMAPTS1PR1S1PR3 | |
| SCHEMBL30570364 | 0.75 | RXRB (0.40) | KDM4EGAAMAPTS1PR1S1PR3 | |
| SCHEMBL22171332 | 0.75 | METAP2 (0.43) | KDM4EMAPTKIF11METAP2GABRA1 | |
| SCHEMBL4787 | 0.74 | CTSS (0.60) | KDM4ECTSSCTSKCNR1CNR2 | |
| SCHEMBL22171364 | 0.74 | METAP2 (0.34) | KDM4EMAPTS1PR1S1PR3KIF11 | |
| SCHEMBL21201421 | 0.73 | IDO1 (0.37) | KIF11GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108779204-B | Olefin polymerization catalyst system and method of using same | 陶氏环球技术有限责任公司 | 2021-06-18 | — | — | CN | disclosed |
| US-10968289-B2 | Olefin polymerization catalyst systems and methods of use thereof | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200277411-A1 | OLEFIN POLYMERIZATION CATALYST SYSTEMS AND METHODS OF USE THEREOF | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3436487-B1 | OLEFIN POLYMERIZATION CATALYST SYSTEMS AND METHODS OF USE THEREOF | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-01-22 | — | — | EP | disclosed |
| EP-3436487-A1 | OLEFIN POLYMERIZATION CATALYST SYSTEMS AND METHODS OF USE THEREOF | Dow Global Technologies, LLC (US) | 2019-02-06 | — | — | EP | disclosed |
| WO-2017173080-A1 | OLEFIN POLYMERIZATION CATALYST SYSTEMS AND METHODS OF USE THEREOF | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-10-05 | — | — | WO | disclosed |
| WO-2017173080-A1 | OLEFIN POLYMERIZATION CATALYST SYSTEMS AND METHODS OF USE THEREOF | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| EP-1988900-A2 | PYRIDINE, PYRIMIDINE AND PYRAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007100610-A2 | PYRIDINE, PYRIMIDINE AND PYRAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007100610-A2 | PYRIDINE, PYRIMIDINE AND PYRAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | CXCR3, CXCR1, CXCR5 | KDM4E 3976/4885GAA 4789/4885MAPT 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.